Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS - Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright restated a "buy" rating and issued a $2.00 price target on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Stock Down 6.5 %

SENS stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.34. 3,743,244 shares of the company were exchanged, compared to its average volume of 2,706,720. The firm has a fifty day simple moving average of $0.37 and a 200 day simple moving average of $0.41. The company has a market capitalization of $180.13 million, a PE ratio of -2.42 and a beta of 0.79. Senseonics has a twelve month low of $0.32 and a twelve month high of $0.75. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. On average, research analysts forecast that Senseonics will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Institutional investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System bought a new position in Senseonics in the 1st quarter worth approximately $91,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Senseonics by 30.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company's stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company's stock valued at $196,000 after purchasing an additional 51,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company's stock valued at $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Senseonics in the first quarter worth about $162,000. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.